ViiV’s HIV regimen hit with setback in the US
US regulators have declined ViiV Healthcare’s application to market an investigational long-acting regimen for the treatment of HIV
Read More
Tag: rilpivirine
ViiV submits regulatory application to EMA for investigational HIV combo
The application is for cabotegravir and Edurant (rilpivirine) as the first monthly, injectable treatment for HIV.
Read More
ViiV submits NDA for first long-acting, injectable HIV combo
The combination of cabotegravir and Edurant has the potential to give people living with HIV one month between doses.
Read More
Encouraging data for ViiV’s long-acting, two-drug HIV therapy
ViiV Healthcare has unveiled encouraging mid-stage data backing a long-acting formulation of its two-drug regimen cabotegravir and rilpivirine for the treatment of HIV.
Read More
ViiV, Janssen’s two-drug HIV regimen hits PhIII targets
ViiV Healthcare and Janssen have unveiled positive headline data from a late-stage trial of their injectable two-drug regimen for the treatment of HIV.
Read More
EU nod for ViiV/Janssen’s two-drug HIV regimen
ViiV Healthcare and Janssen have announced the approval of Juluca in Europe as the first two-drug regimen to treat some patients with HIV.
Read More
Six new therapies backed for EU approval
Six medicines have taken a big step towards European approval having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
ViiV trials long-acting, two-drug HIV regimen
ViiV Healthcare has kicked off a late-stage study testing a long-acting, two-drug regimen of its cabotegravir and Janssen’s rilpivirine in virally suppressed adults with HIV-1 infection
Read More
ViiV’s long-acting two-drug HIV regimen hits targets
A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence.
Read More
ViiV/Janssen’s two-drug HIV regimen filed in US, EU
ViiV Healthcare has filed a single-tablet, two-drug regimen of its dolutegravir and Janssen’s rilpivirine with regulators in both the US and EU.
Read More
ViiV study shows efficacy of two-drug HIV regimen
ViiV Healthcare has unveiled late-stage data showing that an experimental two-drug regimen of its dolutegravir and Janssen Science’s rilpivirine was comparable in efficacy to three- or four-drug antiretroviral regimens in virologically suppressed patients.
Read More
ViiV kicks off PhIII trials of HIV regimen
ViiV Healthcare has kicked off two late stage studies assessing a potential new regimen for the treatment of HIV-1 infection.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
